Ads
related to: aha guideline atrial fibrillation
Search results
Results From The WOW.Com Content Network
risk of stroke (for non-rheumatic atrial fibrillation) The CHADS 2 score and its updated version, the CHA 2 DS 2 -VASc score , are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke.
Atrial fibrillation is associated with an increased risk of heart failure, dementia, and stroke. [3] [12] It is a type of supraventricular tachycardia. [14] Atrial fibrillation frequently results from bursts of tachycardia that originate in muscle bundles extending from the atrium to the pulmonary veins. [15]
Advanced cardiac life support, advanced cardiovascular life support (ACLS) refers to a set of clinical guidelines established by the American Heart Association (AHA) for the urgent and emergent treatment of life-threatening cardiovascular conditions that will cause or have caused cardiac arrest, using advanced medical procedures, medications, and techniques.
According to the ACC/AHA guidelines, intravenous digoxin (cardiac glycoside) can be used in atrial fibrillation (Afib) to assist heartbeats. [90] In multicenter randomised controlled trials, intravenous digoxin was shown to be effective in controlling the heart rate compared to a placebo. [91] [92]
In 2003, the AHA and the American Stroke Association created the Get With the Guidelines (GWTG)-Stroke program. [79] It is a voluntary registry that hospitals can use to receive the latest scientific treatment guidelines. [80] The program also collects data on patient characteristics, hospital adherence to guidelines, and patient outcomes. [79]
"2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines". Journal of the American College of Cardiology. 62 (16): e147 – e239. doi: 10.1016/j.jacc.2013.05.019. ISSN 0735-1097. OCLC 5164937317. PMID 23747642.
Atrial fibrillation is the most common heart rhythm disorder, affecting 2 to 3% of the population of Europe and North America.It is the cause of 20–25% of ischemic brain strokes.
A wearable cardioverter defibrillator (WCD) is a non-invasive, external device for patients at risk of sudden cardiac arrest (SCA). [1] It allows physicians time to assess their patient's arrhythmic risk and see if their ejection fraction improves before determining the next steps in patient care.